Macrotrends gilead. 04B , a 5. Stock Screener Gilead Sciences receivables from 2010 to 2024. Gilead Sciences basic eps for the twelve months ending June 30, 2024 was $0. Gilead Sciences book value per share for the three months ending June 30, 2024 was $14. 07% increase year-over-year. Gilead Sciences other non-current liabilities for the quarter ending Current and historical days sales in receivables for Gilead Sciences (GILD) from 2010 to 2024. Gilead Sciences net income for the quarter ending June 30, 2024 was $1. Market Indexes. 55B , a 39. Gilead Sciences other non-current liabilities from 2010 to 2024. 385B , a 2. Gilead Sciences property, plant, and equipment for the quarter ending June 30, Gilead Sciences accrued expenses from 2010 to 2024. 001B, a 0% increase year-over-year. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities. Gilead Sciences total liabilities for 2022 were $41. Gilead Sciences annual/quarterly net current debt history and growth rate from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Operating cash flow per share can be defined as a measure of financial performance calculated as operating cash flow, expressed on a per share basis Gilead Sciences operating cash flow per share for the three months ending June 30, 2024 was $2. 438B , a 20. 579B , a 14. Gilead Sciences net income for the Gilead Sciences debt/equity for the three months ending June 30, 2024 was 1. Book value per share can be defined as the amount of equity available to shareholders expressed on a per common share basis. Gilead Sciences free cash flow for the quarter ending June 30, 2024 was 3,309. 772B , a 58. Gilead Sciences annual revenue for 2021 was $27. 00: Bristol Myers Squibb (BMY) Gilead Sciences annual/quarterly gross profit history and growth rate from 2010 to 2024. 42% decline year-over-year. Interactive chart of historical stock value for Gilead Sciences over the last 10 years. 264B , a 13. 002B , a 97. 962B , a 10. 18 . 558B, a 69. Stock Research. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for. ; Gilead Sciences Current and historical return on assets (ROA) values for Gilead Sciences (GILD) over the last 10 years. Gilead Sciences net income/loss for the twelve months ending June 30, 2024 was $3. Gilead Sciences total current liabilities for 2023 were $11. Gilead Sciences accounts payable for 2023 were $0. 537B , a 13. 07% decline from 2021. 58% increase from Soligenix gross margin from 2010 to 2024. 028B , a 1300% increase from 2022. Return on assets can be defined as an indicator of how profitable a company is relative At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. 66B, a 2. 52B , a 11. Gilead Sciences total current liabilities for the quarter ending September 30, 2024 were $10. Gilead Sciences basic shares outstanding for the quarter ending June 30, 2024 were $1. Gilead Sciences sg&a expenses for the twelve months ending The current gross profit margin for Gilead Sciences as of June 30, 2024 is % . Gilead Sciences cost of goods sold for the quarter ending June 30, 2024 was $1. 21% decline year-over-year. Current and historical free cash flow per share for Gilead Sciences (GILD) from 2010 to 2024. 305B, a 10. Current and historical gross margin, operating margin and net profit margin for Gilead Sciences (GILD) over the last 10 years. Net profit margin can be defined as net Income as a portion of total sales revenue. 28% increase year-over-year. 171B , a 7. (GILD) stock, including valuation metrics, financial numbers, share information and more. Please register using your email address to continue enjoying our free content. Gilead Sciences total assets for the quarter ending June 30, 2024 were $53. Gross profit can be defined as the profit a company makes after deducting the variable costs directly Get Gilead Sciences Inc (GILD. 083B , a 70 The current operating profit margin for Gilead Sciences as of September 30, 2024 is 19. 026B, a 24. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. ; Gilead Sciences accrued expenses for 2023 were $3. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately. Gilead Sciences annual/quarterly revenue history and growth rate Based on 23 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy. Gilead Sciences annual basic eps for 2023 was $0. " Out of the 23 analysts, 11 Gilead Sciences market value as of October 16, 2024 is $108B. Gilead Sciences cash on hand for 2022 was $6. Market Current and historical return on equity (ROE) values for Gilead Sciences (GILD) over the last 10 years. Gilead Sciences other long-term assets from 2010 to 2024. Gilead Sciences pre-tax profit margin for the three months ending June 30, 2024 was . Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. 579B, a 14. Gilead Sciences annual/quarterly net income history and growth rate from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares. Gilead Sciences cash on hand for 2023 was $7. 093B , a 830% increase year-over-year. 76 . 84% increase year-over Gilead Sciences annual/quarterly free cash flow history and growth rate from 2010 to 2024. - Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts toward Ending the Epidemic Gilead Sciences, Inc. Gilead Sciences total long-term assets for Gilead Sciences annual/quarterly pre-tax income history and growth rate from 2010 to 2024. 45% increase year-over-year. 787B, a 18. The current TTM dividend payout for Gilead Sciences (GILD) as of October 22, 2024 is $3. Gilead Sciences inventory turnover ratio for the three months ending June 30, 2024 was 0. Gilead Sciences comprehensive income for 2021 was Historical dividend payout and yield for Gilead Sciences (GILD) since 2017. 59% decline from 2021. Gilead Sciences cash flow from Gilead Sciences property, plant, and equipment from 2010 to 2024. Gilead Sciences Annual Market Value. Please see the "Historical Prices" tab for adjusted price values. 28% increase from 2022. 125B, a 1. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately. 705B , a Gilead Sciences annual/quarterly basic shares outstanding history and growth rate from 2010 to 2024. Gilead Sciences accounts payable for 2022 were $0. The current dividend yield for Gilead Sciences as of October 22, 2024 is 3. Common stock net can be defined as the value of common equity ownership. 382B , a 14. 096B , a 8. 26% increase year-over-year. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. 247B , a 0. Gilead Sciences gross profit for the quarter ending September 30, 2024 was $5. If you experience any issues with this process, please contact us for further assistance. 37% increase from 2021. 91% decline from 2021. 04% Current and historical return on tangible equity values for Gilead Sciences (GILD) over the last 10 years. 45% decline from 2022. Treasury stock can be defined as common shares bought back by the issueing company and held in its treasury Gilead Sciences annual/quarterly income after taxes history and growth rate from 2010 to 2024. Days sales in receivables can be defined as the average number of days it takes to collect outstanding receiveable amounts from customers. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period. 65 . 125B , a 1. 376B , a 6. Gilead Sciences Quarterly Market Value. Current and historical operating margin for Gilead Sciences (GILD) over the last 10 years. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. 28B , Gilead Sciences annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Current and historical EBIT (Earnings Before Interest & Taxes) margin for Gilead Sciences (GILD) over the last 10 years. Gilead Sciences annual/quarterly other income history and growth rate from 2010 to 2024. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it Ten years of annual and quarterly financial statements and annual report data for Gilead Sciences (GILD). Stock Screener. 67% . Gilead Sciences free cash flow for the twelve months ending Gilead Sciences total liabilities for the quarter ending June 30, 2024 were $35. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement Gilead Sciences total depreciation and amortization - cash flow for the quarter ending June 30, 2024 Gilead Sciences accounts payable for the quarter ending June 30, 2024 were $0. 005B , a 24. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Gilead Sciences inventory for the quarter ending June 30, 2024 was $2. 16% decline year-over The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Precious Metals Register to Continue Using Current and historical book value per share for Gilead Sciences (GILD) from 2010 to 2024. Gilead Sciences total liabilities and share holders equity for 2022 was $63. Prices shown are actual historical values and are not adjusted for either splits or dividends. 614B , a 54. 26% increase from 2022. Current and historical debt to equity ratio values for Gilead Sciences (GILD) over the last 10 years. 29 , a 53. Gilead Sciences comprehensive income for 2023 was $0. 16% decline from 2022. Gilead Sciences other long-term assets for the quarter ending June 30, 2024 were Gilead Sciences common stock net from 2010 to 2024. 93: Vertex Pharmaceuticals (VRTX) United States: $121. Gilead Sciences pre-tax income for the quarter ending June 30, 2024 was $2. 08 . 07% Gilead Sciences total assets from 2010 to 2024. Gilead Sciences total long term liabilities for 2022 were $30. 262B , a 14. ; Gilead Sciences receivables for 2023 were $4. 08% decline from 2022. Gilead Sciences net profit margin as of June 30, 2024 is 3. Gilead Sciences basic eps for the quarter ending June 30, 2024 was $1. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Gilead Sciences accrued expenses for the quarter ending June 30, 2024 were $3. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year. 8% increase year-over-year. 749B, a 7. 433B , a 8. 60 . ; Gilead Sciences Gilead Sciences annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. 053B , a 29. 923B, a 12. 00 , a year-over-year. 205B: 16. The current operating profit margin for Gilead Sciences as of September 30, 2024 is 19. Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a Current and historical current ratio for Gilead Sciences (GILD) from 2010 to 2023. Gilead Sciences share holder equity from 2010 to 2024. Return on equity can be defined as the amount of net income returned as a percentage Current and historical return on assets (ROA) values for Gilead Sciences (GILD) over the last 10 years. Gilead Sciences treasury stock from 2010 to 2024. 51% decline from 2021. Gilead Sciences income after taxes for the quarter ending Current and historical pre-tax profit margin for Gilead Sciences (GILD) from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone. Gilead Sciences annual Gilead Sciences annual/quarterly non-controlling interest history and growth rate from 2010 to 2024. Gilead Sciences annual/quarterly total depreciation and amortization - cash flow history and growth rate from 2010 to 2024. 83 . Register to Continue Using Macrotrends. 603B , a 9. The current EBIT profit margin for Gilead Sciences as of June 30, 2024 is . Gilead Sciences cash on hand for 2021 was $6. 663B, a 10. Gilead Sciences EBIT for the quarter ending June 30, 2024 was $2. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field. The value of a company is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. ; Gilead Sciences EBIT for the twelve months ending June 30, 2024 was $2. 57% increase year-over-year. Gilead Sciences common stock net for the quarter ending June 30, 2024 was $0. 79% decline year-over-year. 13% decline year-over-year. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures. 644B, a 58. (/ ˈɡɪliəd /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the Gilead Sciences total assets from 2010 to 2023. EBIT can be defined as earnings before interest and taxes. Free cash flow per share can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis Gilead Sciences free cash flow per share for the three months ending June 30, 2024 was $2. 544B , a 13. At Gilead, we promise to treat your data with respect. Receivables can be defined as the total amount of collectibles for a company Gilead Sciences receivables for the quarter ending June 30, 2024 were $4. Gilead Sciences cash flow from operating activities for the quarter ending September 30, 2024 was $3. Total long-term assets can be defined as the sum of all assets classified as non-current Gilead Sciences total long-term assets for the quarter ending June 30, 2024 were $41. 73% decline year-over-year. 802B, a 9. Share holder equity can be defined as the sum of preferred and common equity items Gilead Sciences share holder equity for the quarter ending September 30, 2024 was $18. Ten years of annual and quarterly financial statements and annual report data for Gilead Sciences (GILD). Gilead Sciences total Current and historical net profit margin for Gilead Sciences (GILD) from 2010 to 2024. ; Gilead Sciences total assets for 2023 were $62. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. 556B , a 226. 52% decline from 2022. Income statements, balance sheets, cash flow statements and key ratios. Stock split history for Gilead Sciences since 1992. 81% decline year-over-year. 84 , a 80. Other income can be defined as any post tax miscellaneous income items. 777B, a Ten years of annual and quarterly financial ratios and margins for analysis of Gilead Sciences (GILD). Gilead Sciences total long term liabilities for 2023 were $28. 28% decline year-over-year. 99% decline from Gilead Sciences annual and quarterly EBIT history from 2010 to 2024. The latest closing stock price for Gilead Sciences as of November 12, Gilead Sciences revenue for the twelve months ending September 30, 2024 was Gilead Sciences market cap history and chart from 2010 to 2024. ; Gilead Sciences common stock net for 2022 Gilead Sciences comprehensive income for the quarter ending June 30, 2024 was $0. Gilead Sciences comprehensive income for 2022 was $0. . 22% decline year-over-year. Gilead Sciences inventory for 2023 was $1. 971B , a 8. 197B, a 13. 56% decline from 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term Current and historical p/e ratio for Gilead Sciences (GILD) from 2010 to 2024. ; Gilead Sciences common stock net for 2023 was $0. 6% increase from 2020. Current and historical gross margin for Gilead Sciences (GILD) over the last 10 years. 55% decline year-over-year. Gilead Sciences annual income taxes for 2023 were $1. Gilead Sciences days sales in receivables for the three months ending June 30, 2024 was 60. 04% increase from 2022. Gilead Sciences annual/quarterly gross profit history and growth rate from 2010 to 2023. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change Gilead Sciences income from continuous operations for the quarter ending Gilead Sciences total liabilities and share holders equity for the quarter ending June 30, 2024 was $53. 544B , a 7. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement Gilead Sciences net income/loss for the quarter ending June 30, 2024 was $-2. Gilead Sciences total long term liabilities for the quarter ending June 30, 2024 were $24. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent Gilead Sciences annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Gilead Sciences total liabilities and share holders equity for 2023 was $62. 001B, a 0% decline from 2022. 725B , a 12. 321B: 0. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. 79% . 35 . The current EBITDA margin for Gilead Sciences as of June 30, 2024 is . ; Gilead Sciences total assets for 2022 were The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. 67% decline year-over-year. 82% decline year-over-year. 23% decline from 2022. Non-controlling interest can be defined as the reporting company's share of ownership in another company by including income or loss of the company as a portion of Net Income Gilead Sciences annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2024. Detailed statistics for Gilead Sciences, Inc. Gilead Sciences annual basic eps for Current and historical operating cash flow per share for Gilead Sciences (GILD) from 2010 to 2024. Gilead Sciences net profit margin for the three months ending June 30, 2024 was . 905B , a 28. Gilead Sciences total liabilities for 2023 were $39. Gilead Sciences total liabilities for 2021 were $46 Gilead Sciences total current liabilities from 2010 to 2024. 66% decline from 2022. Gilead Sciences income taxes for the twelve months ending June 30, 2024 were $505M , a 73. Gilead Sciences total long-term assets for 2023 were $46. Historical daily share price chart and data for Gilead Sciences since 1992 adjusted for splits and dividends. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Stock Screener Gilead Sciences cash on hand for the quarter ending June 30, 2024 was $2. Total assets can be defined as the sum of all assets on a company's balance sheet. ; Gilead Sciences 2023 Current and historical inventory turnover ratio for Gilead Sciences (GILD) from 2010 to 2024. 781B , a 22. ; Gilead Sciences receivables for 2022 were $4. Calculated by dividing a company's operating earnings by its total assets. Cash flow from operating activities can be defined as a company's cash flows from operations. 05% decline year-over-year. Gilead Sciences annual/quarterly other operating income or expenses history and growth rate from 2010 to 2024. Gilead Sciences market value as of October 16, 2024 is $108B . Stock Name Country Market Cap PE Ratio; Amgen (AMGN) United States: $169. Gilead Sciences pre-tax income for the twelve months Gilead Sciences income taxes for the quarter ending June 30, 2024 were $0. ; Gilead Sciences share holder equity for 2023 was $22. Compare GILD With Other Stocks. Gilead Sciences accounts payable for 2021 were $0. 77% increase from 2022. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Gilead Sciences sg&a expenses for the quarter ending September 30, 2024 were $1. 18% decline year-over-year. Gilead Sciences, Inc. Accrued expenses can be defined as expenses that have been incurred but not paid. 49% . 97% increase year-over-year. By providing your email address below, you are providing consent to Gilead to send you the requested Investor Email Alert Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Gilead Sciences (GILD) over the last 10 years. tdzjt orelv gpqbx oibgqx xtpac yznj daavur nnoo jvg fzkovz